Aarti Pharmalabs Ltd (NSE: AARTIPHARM, BSE: 543748) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹7,922 Cr, it ranks #669 by market cap among the 6,137 Indian listed companies on FinBizNet, and #4 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹820.85 (as of 25 Oct 2026), the share price is 18.1% below its 52-week high of ₹1,002.40 and 40.3% above its 52-week low of ₹585.00. The share price is down 4.1% over one year and up 21.8% over three months.
| Current Price | ₹820.85 |
|---|---|
| Market Cap | ₹7,922 Cr |
| NSE Symbol | AARTIPHARM |
| BSE Code | 543748 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 43.2 |
| Return on Equity | 8.49% |
| Return on Assets | 5.84% |
| 52-Week Range | ₹585.00 – ₹1,002.40 |
| 1-Year Price Change | -4.1% |
| 3-Month Price Change | +21.8% |
| Beta (1Y) | 0.49 |
| Dividend Yield | 0.48% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aartipharmalabs.com |
| Revenue | ₹536 Cr |
|---|---|
| Net Profit | ₹69 Cr |
| Net Margin | 12.8% |
| EPS (Basic) | ₹8.40 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalab
1. Pharmacuticals-This segment engages in the manufacturing and sale of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmeceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,73,448 Cr | 71.2 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹20,419 Cr | 92.1 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹16,073 Cr | 27.7 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,922 Cr | 43.2 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹3,361 Cr | -382.6 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,153 Cr | 110.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹556 Cr | 25.9 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹501 Cr | 24.8 | — | — | +39.4% |
| Infinium Pharmachem Limited | ₹475 Cr | 37.6 | — | — | +13.5% |
Listed by market capitalisation. Ratios are shown for context only.
Aarti Pharmalabs Ltd is trading at ₹820.85, with a market capitalisation of ₹7,922 Cr.
Aarti Pharmalabs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Aarti Pharmalabs Ltd has a P/E of 43.2 and a return on equity of 8.49%.
Aarti Pharmalabs Ltd is listed on the NSE under the symbol AARTIPHARM and on the BSE under the scrip code 543748.
Aarti Pharmalabs Ltd's share price is down 4.1% over one year and up 21.8% over three months. Its 52-week range is ₹585.00 to ₹1,002.40.
In Q1 FY27, Aarti Pharmalabs Ltd reported revenue of ₹536 Cr and net profit of ₹69 Cr, with basic EPS of ₹8.4 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.